169 related articles for article (PubMed ID: 38577531)
1. Associations of
Choochuay K; Kunhapan P; Puangpetch A; Tongsima S; Srisawasdi P; Sobhonslidsuk A; Sungkanuparph S; Biswas M; Sukasem C
World J Hepatol; 2024 Mar; 16(3):366-378. PubMed ID: 38577531
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
[TBL] [Abstract][Full Text] [Related]
3. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population.
Lee GH; Phyo WW; Loo WM; Kwok R; Ahmed T; Shabbir A; So J; Koh CJ; Hartono JL; Muthiah M; Lim K; Tan PS; Lee YM; Lim SG; Dan YY
World J Hepatol; 2020 Dec; 12(12):1228-1238. PubMed ID: 33442450
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
[TBL] [Abstract][Full Text] [Related]
7. Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.
Mazzini FN; Cook F; Gounarides J; Marciano S; Haddad L; Tamaroff AJ; Casciato P; Narvaez A; Mascardi MF; Anders M; Orozco F; Quiróz N; Risk M; Gutt S; Gadano A; Méndez García C; Marro ML; Penas-Steinhardt A; Trinks J
Metabolomics; 2021 Jun; 17(7):58. PubMed ID: 34137937
[TBL] [Abstract][Full Text] [Related]
8. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B.
Pan Q; Zhang RN; Wang YQ; Zheng RD; Mi YQ; Liu WB; Shen F; Chen GY; Lu JF; Zhu CY; Zhang SY; Chen YM; Sun WL; Fan JG
World J Gastroenterol; 2015 Jul; 21(28):8605-14. PubMed ID: 26229402
[TBL] [Abstract][Full Text] [Related]
9. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
[TBL] [Abstract][Full Text] [Related]
10. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.
Liu WY; Eslam M; Zheng KI; Ma HL; Rios RS; Lv MZ; Li G; Tang LJ; Zhu PW; Wang XD; Byrne CD; Targher G; George J; Zheng MH
J Clin Transl Hepatol; 2021 Apr; 9(2):194-202. PubMed ID: 34007801
[TBL] [Abstract][Full Text] [Related]
11. Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia.
Chihota BV; Riebensahm C; Muula G; Sinkala E; Chilengi R; Mulenga L; Bosomprah S; Vinikoor MJ; Bolton-Moore C; Egger M; Rauch A; Berzigotti A; Wandeler G;
BMJ Open Gastroenterol; 2022 Jul; 9(1):. PubMed ID: 35831020
[TBL] [Abstract][Full Text] [Related]
12.
Gu Z; Bi Y; Yuan F; Wang R; Li D; Wang J; Hu X; He G; Zhang L; Liu BC
Clin Interv Aging; 2020; 15():1333-1341. PubMed ID: 32848374
[TBL] [Abstract][Full Text] [Related]
13. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
[TBL] [Abstract][Full Text] [Related]
14. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.
Hotta K; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A
BMC Med Genet; 2010 Dec; 11():172. PubMed ID: 21176169
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.
Liu Z; Lin C; Suo C; Zhao R; Jin L; Zhang T; Chen X
Metabolism; 2022 Feb; 127():154955. PubMed ID: 34915036
[TBL] [Abstract][Full Text] [Related]
17. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.
Scheiner B; Mandorfer M; Schwabl P; Payer BA; Bucsics T; Bota S; Aichelburg MC; Grabmeier-Pfistershammer K; Stättermayer A; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
PLoS One; 2015; 10(11):e0143429. PubMed ID: 26599080
[TBL] [Abstract][Full Text] [Related]
18. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.
Falleti E; Fabris C; Cmet S; Cussigh A; Bitetto D; Fontanini E; Fornasiere E; Bignulin S; Fumolo E; Bignulin E; Pirisi M; Toniutto P
Liver Int; 2011 Sep; 31(8):1137-43. PubMed ID: 21745286
[TBL] [Abstract][Full Text] [Related]
19. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
[TBL] [Abstract][Full Text] [Related]
20. A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease.
Perez-Diaz-Del-Campo N; Dileo E; Castelnuovo G; Nicolosi A; Guariglia M; Caviglia GP; Rosso C; Armandi A; Bugianesi E
Clin Nutr; 2023 Nov; 42(11):2181-2187. PubMed ID: 37788561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
